Saudi King Salman to undergo medical tests for lung inflammation
Adds details, background
Oct 6 (Reuters) -Saudi King Salman will undergo medical tests on Sunday evening for lung inflammation, the state news agency said, citing a statement from the royal court.
The brief statement did not reveal more details.
The 88-year-old king of the world's biggest oil exporter, a major U.S. ally in the Middle East, also received medical care for lung inflammation in May.
Salman last chaired a cabinet meeting in August, less than two weeks after a royal decree issued by him allowed the cabinet to convene in the absence of the king, crown prince or both.
The decree said that in their absence it would be chaired by the eldest member of the cabinet who is a descendant of Salman's father King Abdulaziz Al Saud, founder of the Saudi state.
Reporting by Ahmed Tolba and Hatem Maher
Editing by Christina Fincher
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
